Nichole A Martin1, Mina Hanna2, Christopher Ehret1, Gladys Asiedu3, Aminah Jatoi4. 1. Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Mayo Clinic Health System, Mayo Clinic, Albert Lea, MN, USA. 3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 4. Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. jatoi.aminah@mayo.edu.
Abstract
PURPOSE: This qualitative study sought to learn patients' perspectives on olaparib - including maintenance olaparib - in their own words. METHODS: Olaparib-treated patients were interviewed by phone. A semi-structured interview guide that focused on symptoms and quality of life was formulated in alignment with the study objective. Interviews were transcribed and analyzed with content analysis. RESULTS: Twenty olaparib-treated patients were interviewed. Four themes emerged: (1) The Long Cancer Journey. Patients prescribed olaparib appear to have had a long cancer journey, sometimes with prior cancer ("I had breast cancer in 1996") and sometimes with a long interval from an ovarian cancer diagnosis; (2) Adherence. Despite this journey, patients were adherent to olaparib ("I set it for an alarm 15 min before I have to take [olaparib] and then exactly when I'm supposed to take it"); (3) Adherence Despite Challenges. Adherence continued despite side effects (although olaparib was "pretty tolerable"). This adherence also continued despite cost ("…for a month's supply, mine was $15,837… and my insurance covered some of it but not near enough"), and (4) Modifications in Perceptions of BRCA Status. Olaparib as cancer therapy influenced perceptions of BRCA mutations ("But I… I have to tell you, I'm grateful that I qualified to be on Lynparza®"). CONCLUSION: Although oral maintenance therapy for ovarian cancer is relatively new, patients appear willing to take olaparib long term; and they seem to take great lengths to remain adherent, despite having sometimes had a long cancer journey.
PURPOSE: This qualitative study sought to learn patients' perspectives on olaparib - including maintenance olaparib - in their own words. METHODS: Olaparib-treated patients were interviewed by phone. A semi-structured interview guide that focused on symptoms and quality of life was formulated in alignment with the study objective. Interviews were transcribed and analyzed with content analysis. RESULTS: Twenty olaparib-treated patients were interviewed. Four themes emerged: (1) The Long Cancer Journey. Patients prescribed olaparib appear to have had a long cancer journey, sometimes with prior cancer ("I had breast cancer in 1996") and sometimes with a long interval from an ovarian cancer diagnosis; (2) Adherence. Despite this journey, patients were adherent to olaparib ("I set it for an alarm 15 min before I have to take [olaparib] and then exactly when I'm supposed to take it"); (3) Adherence Despite Challenges. Adherence continued despite side effects (although olaparib was "pretty tolerable"). This adherence also continued despite cost ("…for a month's supply, mine was $15,837… and my insurance covered some of it but not near enough"), and (4) Modifications in Perceptions of BRCA Status. Olaparib as cancer therapy influenced perceptions of BRCA mutations ("But I… I have to tell you, I'm grateful that I qualified to be on Lynparza®"). CONCLUSION: Although oral maintenance therapy for ovarian cancer is relatively new, patients appear willing to take olaparib long term; and they seem to take great lengths to remain adherent, despite having sometimes had a long cancer journey.
Authors: Isabelle Ray-Coquard; Patricia Pautier; Sandro Pignata; David Pérol; Antonio González-Martín; Regina Berger; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Johanna Mäenpää; Frédéric Selle; Jalid Sehouli; Domenica Lorusso; Eva M Guerra Alía; Alexander Reinthaller; Shoji Nagao; Claudia Lefeuvre-Plesse; Ulrich Canzler; Giovanni Scambia; Alain Lortholary; Frederik Marmé; Pierre Combe; Nikolaus de Gregorio; Manuel Rodrigues; Paul Buderath; Coraline Dubot; Alexander Burges; Benoît You; Eric Pujade-Lauraine; Philipp Harter Journal: N Engl J Med Date: 2019-12-19 Impact factor: 91.245
Authors: Michael Friedlander; Val Gebski; Emma Gibbs; Lucy Davies; Ralph Bloomfield; Felix Hilpert; Lari B Wenzel; Daniel Eek; Manuel Rodrigues; Andrew Clamp; Richard T Penson; Diane Provencher; Jacob Korach; Tomasz Huzarski; Laura Vidal; Vanda Salutari; Clare Scott; Maria Ornella Nicoletto; Kenji Tamura; David Espinoza; Florence Joly; Eric Pujade-Lauraine Journal: Lancet Oncol Date: 2018-07-17 Impact factor: 41.316
Authors: Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Philip Rowe; Elizabeth Lowe; Darren Hodgson; Mika A Sovak; Ursula Matulonis Journal: Lancet Oncol Date: 2016-09-09 Impact factor: 41.316
Authors: Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro Journal: N Engl J Med Date: 2018-10-21 Impact factor: 91.245
Authors: Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Bryan Bennett; David Parry; Stuart Spencer; Helen Mann; Ursula Matulonis Journal: Br J Cancer Date: 2016-11-08 Impact factor: 7.640
Authors: Gladys B Asiedu; Jennifer L Ridgeway; Katherine Carroll; Aminah Jatoi; Carmen Radecki Breitkopf Journal: Health Expect Date: 2018-04-14 Impact factor: 3.377